Literature DB >> 31830857

The Cerebral Thrombin System Is Activated after Intracerebral Hemorrhage and Contributes to Secondary Lesion Growth and Poor Neurological Outcome in C57Bl/6 Mice.

Harald Krenzlin1,2, Eva Gresser1, Daniel Jussen1,3, Nicole Riede1, Louise Taylor1, Christina Francisca Vogelaar4, Florian Ringel1,2, Oliver Kempski1, Beat Alessandri1.   

Abstract

With increasing evidence for the existence of a cerebral thrombin system, coagulation factor IIa (thrombin) is suspected to influence the pathogenesis of secondary injury progression after intracerebral hemorrhage (ICH). We hypothesized that mechanisms associated with local volume expansion after ICH, rather than blood constituents, activate the cerebral thrombin system and are responsible for detrimental neurological outcome. To test this hypothesis, we examine the local thrombin expression after ICH in a C57BL/6N mouse model in the presence and absence of blood constituents. ICH was established using stereotaxic orthotopic injection of utologous blood (n = 10) or silicone oil as inert volume substance (n = 10) into the striatum. Intracranial pressure (ICP), cerebral blood flow (CBF), and mean arterial blood pressure (MAP) were monitored during and 30 min after the procedure. No significant differences between ICP, CBF, and MAP were found between both groups. Prothrombin messenger RNA expression was upregulated early after ICH. Immunohistochemistry showed an increase of perilesional thrombin in both groups (blood, 4.24-fold; silicone, 3.10-fold), whereas prothrombin fragment (F1.2) was elevated only in the absence of whole blood. Thrombin expression is colocalized with neuronal antigen expression. After 24 h, lesion size and neuronal loss were similar. Perihematomal thrombin correlated with increased neuronal loss and detrimental neurological outcome in vivo. In our study, we demonstrate, for the first time, that the local cerebral thrombin system is activated after ICH and that this activation is independent of the presence of whole-blood constituents. In our study, neuronal damage is driven by local thrombin expression and leads to an adverse clinical outcome.

Entities:  

Keywords:  cerebral thrombin system; intracranial hemorrhage; secondary injury; thrombin

Year:  2020        PMID: 31830857     DOI: 10.1089/neu.2019.6582

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  5 in total

1.  [Suppression of HMGB1 inhibits neuronal autophagy and apoptosis to improve neurological deficits in rats following intracerebral hemorrhage].

Authors:  L Zhang; S Miao; Z Yang; Z Li; Y Fan; K Yu; K Huang; Q Huang; X Xia
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-07-20

2.  Hemostasis functions are associated with hemorrhagic transformation in non-atrial fibrillation patients: a case-control study.

Authors:  Hao-Ran Cheng; Yun-Bin Chen; Ya-Ying Zeng; Yi-Ting Ruan; Cheng-Xiang Yuan; Qian-Qian Cheng; Hui-Jun Chen; Xiao-Qian Luan; Gui-Qian Huang; Jin-Cai He
Journal:  BMC Neurol       Date:  2021-01-26       Impact factor: 2.474

3.  LncRNA TCONS_00145741 Knockdown Prevents Thrombin-Induced M1 Differentiation of Microglia in Intracerebral Hemorrhage by Enhancing the Interaction Between DUSP6 and JNK.

Authors:  Lanxiang Wu; Qingqing Zhan; Pan Liu; Heqing Zheng; Mingxu Liu; Jun Min; Liang Xie; Wei Wu
Journal:  Front Cell Dev Biol       Date:  2022-01-19

Review 4.  Effects of Thrombin on the Neurovascular Unit in Cerebral Ischemia.

Authors:  Hui Cao; Sai Wang Seto; Deep Jyoti Bhuyan; Hoi Huen Chan; Wenting Song
Journal:  Cell Mol Neurobiol       Date:  2021-01-03       Impact factor: 5.046

5.  High CSF thrombin concentration and activity is associated with an unfavorable outcome in patients with intracerebral hemorrhage.

Authors:  Harald Krenzlin; Christina Frenz; Jan Schmitt; Julia Masomi-Bornwasser; Dominik Wesp; Darius Kalasauskas; Thomas Kerz; Johannes Lotz; Beat Alessandri; Florian Ringel; Naureen Keric
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.